TY - JOUR
T1 - Serum B vitamin levels and risk of lung cancer
AU - Johansson, Mattias
AU - Relton, Caroline
AU - Ueland, Per Magne
AU - Vollset, Stein Emil
AU - Midttun, Øivind
AU - Nygård, Ottar
AU - Slimani, Nadia
AU - Boffetta, Paolo
AU - Jenab, Mazda
AU - Clavel-Chapelon, Françoise
AU - Boutron-Ruault, Marie Christine
AU - Fagherazzi, Guy
AU - Kaaks, Rudolf
AU - Rohrmann, Sabine
AU - Boeing, Heiner
AU - Weikert, Cornelia
AU - Bas Buenode-Mesquita, H.
AU - Ros, Martine M.
AU - Van Gils, Carla H.
AU - Peeters, Petra H.M.
AU - Agudo, Antonio
AU - Barricarte, Aurelio
AU - Navarro, Carmen
AU - Rodríguez, Laudina
AU - Sánchez, Maria José
AU - Larrañaga, Nerea
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Allen, Naomi E.
AU - Crowe, Francesca
AU - Gallo, Valentina
AU - Norat, Teresa
AU - Krogh, Vittorio
AU - Masala, Giovanna
AU - Panico, Salvatore
AU - Sacerdote, Carlotta
AU - Tumino, Rosario
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Rasmuson, Torgny
AU - Hallmans, Göran
AU - Riboli, Elio
AU - Vineis, Paolo
AU - Brennan, Paul
PY - 2010/6/16
Y1 - 2010/6/16
N2 - Context: B vitamins and factors related to 1-carbon metabolism help to maintain DNA integrity and regulate gene expression and may affect cancer risk. Objective: To investigate if 1-carbon metabolism factors are associated with onset of lung cancer. Design, Setting, and Participants: The European Prospective Investigation into Cancer and Nutrition (EPIC) recruited 519 978 participants from 10 countries between 1992 and 2000, of whom 385 747 donated blood. By 2006, 899 lung cancer cases were identified and 1770 control participants were individually matched by country, sex, date of birth, and date of blood collection. Serum levels were measured for 6 factors of 1-carbon metabolism and cotinine. Main Outcome Measure: Odds ratios (ORs) of lung cancer by serum levels of 4 B vitamins (B2, B6, folate [B 9], and B12), methionine, and homocysteine. Results: Within the entire EPIC cohort, the age-standardized incidence rates of lung cancer (standardized to the world population, aged 35-79 years) were 6.6, 44.9, and 156.1 per 100 000 person-years among never, former, and current smokers formen, respectively. The corresponding incidence rates for women were 7.1, 23.9, and 100.9 per 100 000 person-years, respectively. After accounting for smoking, a lower risk for lung cancer was seen for elevated serum levels of B6 (fourth vs first quartile OR, 0.44; 95% confidence interval [CI], 0.33-0.60; P for trend <.000001), as well as for serum methionine (fourth vs first quartile OR, 0.52; 95% CI, 0.39-0.69; P for trend <.000001). Similar and consistent decreases in risk were observed in never, former, and current smokers, indicating that results were not due to confounding by smoking. The magnitude of risk was also constant with increasing length of follow-up, indicating that the associations were not explained by preclinical disease. A lower risk was also seen for serum folate (fourth vs first quartile OR, 0.68; 95% CI, 0.51-0.90; P for trend =.001), although this was apparent only for former and current smokers. When participants were classified by median levels of serum methionine and B6, having above-median levels of both was associated with a lower lung cancer risk overall (OR, 0.41; 95% CI, 0.31-0.54), as well as separately among never (OR, 0.36; 95% CI, 0.18-0.72), former (OR, 0.51; 95% CI, 0.34-0.76), and current smokers (OR,0.42; 95% CI, 0.27-0.65). Conclusion: Serum levels of vitamin B6 and methionine were inversely associated with risk of lung cancer.
AB - Context: B vitamins and factors related to 1-carbon metabolism help to maintain DNA integrity and regulate gene expression and may affect cancer risk. Objective: To investigate if 1-carbon metabolism factors are associated with onset of lung cancer. Design, Setting, and Participants: The European Prospective Investigation into Cancer and Nutrition (EPIC) recruited 519 978 participants from 10 countries between 1992 and 2000, of whom 385 747 donated blood. By 2006, 899 lung cancer cases were identified and 1770 control participants were individually matched by country, sex, date of birth, and date of blood collection. Serum levels were measured for 6 factors of 1-carbon metabolism and cotinine. Main Outcome Measure: Odds ratios (ORs) of lung cancer by serum levels of 4 B vitamins (B2, B6, folate [B 9], and B12), methionine, and homocysteine. Results: Within the entire EPIC cohort, the age-standardized incidence rates of lung cancer (standardized to the world population, aged 35-79 years) were 6.6, 44.9, and 156.1 per 100 000 person-years among never, former, and current smokers formen, respectively. The corresponding incidence rates for women were 7.1, 23.9, and 100.9 per 100 000 person-years, respectively. After accounting for smoking, a lower risk for lung cancer was seen for elevated serum levels of B6 (fourth vs first quartile OR, 0.44; 95% confidence interval [CI], 0.33-0.60; P for trend <.000001), as well as for serum methionine (fourth vs first quartile OR, 0.52; 95% CI, 0.39-0.69; P for trend <.000001). Similar and consistent decreases in risk were observed in never, former, and current smokers, indicating that results were not due to confounding by smoking. The magnitude of risk was also constant with increasing length of follow-up, indicating that the associations were not explained by preclinical disease. A lower risk was also seen for serum folate (fourth vs first quartile OR, 0.68; 95% CI, 0.51-0.90; P for trend =.001), although this was apparent only for former and current smokers. When participants were classified by median levels of serum methionine and B6, having above-median levels of both was associated with a lower lung cancer risk overall (OR, 0.41; 95% CI, 0.31-0.54), as well as separately among never (OR, 0.36; 95% CI, 0.18-0.72), former (OR, 0.51; 95% CI, 0.34-0.76), and current smokers (OR,0.42; 95% CI, 0.27-0.65). Conclusion: Serum levels of vitamin B6 and methionine were inversely associated with risk of lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=77953633351&partnerID=8YFLogxK
U2 - 10.1001/jama.2010.808
DO - 10.1001/jama.2010.808
M3 - Article
C2 - 20551408
AN - SCOPUS:77953633351
SN - 0098-7484
VL - 303
SP - 2377
EP - 2385
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 23
ER -